| AZD1656 / AstraZeneca |
NCT00790153: To Evaluate the Hormonal Response to Low Blood Sugar After a Single Oral Dose of AZD1656 Suspension |
|
|
| Completed | 1 | 12 | US | Insulin, AZD1656 | AstraZeneca | Type 2 Diabetes | | 02/09 | | |
NCT00768105: To Evaluate Safety and Tolerability After Multiple Oral Doses of AZD1656 in Type 2 Diabetes Patients on Top of Insulin |
|
|
| Completed | 1 | 24 | US | AZD1656, Placebo | AstraZeneca | Type 2 Diabetes | 03/09 | 03/09 | | |
MAD, NCT00747175: A Study to Evaluate Safety, Tolerability and P-Glucose After Multiple Ascending Oral Doses of AZD1656 in Type 2 Diabetes |
|
|
| Completed | 1 | 52 | US | AZD1656 | AstraZeneca | Type 2 Diabetes | 04/09 | 04/09 | | |
NCT00817271: To Evaluate the Response to Glucagon During Hypoglycemia |
|
|
| Completed | 1 | 8 | US | AZD1656, Glucagon | AstraZeneca | Type 2 Diabetes | 04/09 | 04/09 | | |
NCT00819884: To Evaluate 24-hr Glucose After OD vs BD AZD1656 |
|
|
| Completed | 1 | 36 | US | AZD1656 | AstraZeneca | Type II Diabetes | 05/09 | 05/09 | | |
ADME, NCT00960791: Study to Assess the Absorption, Distribution, Metabolism and Excretion of AZD1656 in Type 2 Diabetes Mellitus (T2DM) |
|
|
| Completed | 1 | 6 | US | AZD1656 | AstraZeneca | Type II Diabetes Mellitus | | 09/09 | | |
NCT00916604: To Study Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD1656 in Japanese Type 2 Diabetes Mellitus (T2DM) Patients |
|
|
| Completed | 1 | 24 | Japan | AZD1656, Placebo | AstraZeneca | Type 2 Diabetes | | 10/09 | | |
NCT00774553: To Evaluate Safety and Tolerability After Multiple Oral Doses of AZD1656 in Type 2 Diabetes Patients on Top of Metformin |
|
|
| Completed | 1 | 70 | US, RoW | AZD1656, Placebo | AstraZeneca | Type 2 Diabetes | | 01/10 | | |
NCT00995787: Safety and Tolerability of AZD1656 in Type 2 Diabetes Mellitus (T2DM) Patients Treated With Metformin and Sulfonylurea |
|
|
| Completed | 1 | 75 | US | AZD1656, Placebo | AstraZeneca | Type II Diabetes Mellitus | 02/10 | 02/10 | | |
NCT01082120: Investigate the Effect of AZD1656 on the Pharmacokinetics of Pioglitazone and Vice Versa in Type 2 Diabetes Mellitus |
|
|
| Completed | 1 | 28 | US | AZD1656, Pioglitazone | AstraZeneca | Type 2 Diabetes Mellitus | 05/10 | 05/10 | | |
NCT01095991: Investigate the Effect of AZD1656 on the Pharmacokinetics of Sitagliptin in Patients With Type 2 Diabetes Mellitus |
|
|
| Completed | 1 | 12 | Europe | AZD1656, Sitagliptin, Januvia | AstraZeneca | Type 2 Diabetes Mellitus | 05/10 | 05/10 | | |
NCT01083212: To Evaluate the Effect of Gemfibrozil on the Pharmacokinetics and Pharmacodynamics of a Single Dose of AZD1656 |
|
|
| Completed | 1 | 19 | Europe | AZD1656, Gemfibrozil, Placebo | AstraZeneca | Type 2 Diabetes Mellitus | 06/10 | 06/10 | | |
NCT01096940: Study To Assess the Pharmacokinetics of AZD1656 During Coadministration With Simvastatin |
|
|
| Completed | 1 | 44 | US | AZD1656, simvastatin | AstraZeneca | Type 2 Diabetes Mellitus | 08/10 | 08/10 | | |
NCT01103609: Investigate the Effect of AZD1656 on the Pharmacokinetics and Pharmacodynamics of Warfarin in Type 2 Diabetes Mellitus (T2DM) Patients |
|
|
| Completed | 1 | 16 | Europe | Warfarin, Placebo, AZD1656 | AstraZeneca | Type 2 Diabetes Mellitus | 08/10 | 08/10 | | |
NCT01069926: To Assess the Pharmacokinetics of AZD1656 and Its Metabolite in Type 2 Diabetes Mellitus Patients |
|
|
| Completed | 1 | 21 | US | AZD1656 | AstraZeneca | Glucose Lowering | 10/10 | 10/10 | | |
NCT01103622: Investigate the Effect of AZD1656 on the Pharmacokinetics of Digoxin in Type 2 Diabetes Mellitus Patients |
|
|
| Completed | 1 | 20 | US | AZD1656, Digoxin, Digacin, Placebo | AstraZeneca | Type 2 Diabetes Mellitus | 12/10 | 12/10 | | |
NCT01221519: A Relative Bioavailability Study Measuring the Extent and Rate of Absorption of Different Tablet Formulations of AZD1656 in Type 2 Diabetes Mellitus (T2DM) Patients |
|
|
| Completed | 1 | 20 | US | AZD1656 | AstraZeneca | Type 2 Diabetes Mellitus, High Blood Sugar | 01/11 | 01/11 | | |
NCT01221545: A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics After High Single Ascending Oral Doses of AZD1656 in T2DM Patients |
|
|
| Completed | 1 | 24 | US | AZD1656, Placebo | AstraZeneca | Type 2 Diabetes Mellitus | 01/11 | 01/11 | | |
